1. Home
  2. CAC vs DRUG Comparison

CAC vs DRUG Comparison

Compare CAC & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Camden National Corporation

CAC

Camden National Corporation

HOLD

Current Price

$50.31

Market Cap

801.9M

Sector

Finance

ML Signal

HOLD

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

HOLD

Current Price

$76.68

Market Cap

856.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAC
DRUG
Founded
1875
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Pharmaceuticals and Biotechnology
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
801.9M
856.4M
IPO Year
1997
N/A

Fundamental Metrics

Financial Performance
Metric
CAC
DRUG
Price
$50.31
$76.68
Analyst Decision
Buy
Strong Buy
Analyst Count
2
6
Target Price
$45.50
$106.75
AVG Volume (30 Days)
105.6K
125.9K
Earning Date
01-27-2026
02-10-2026
Dividend Yield
3.35%
N/A
EPS Growth
6.08
N/A
EPS
3.84
N/A
Revenue
$233,489,000.00
N/A
Revenue This Year
$19.32
N/A
Revenue Next Year
$5.90
N/A
P/E Ratio
$13.05
N/A
Revenue Growth
31.62
N/A
52 Week Low
$34.53
$23.18
52 Week High
$51.57
$123.75

Technical Indicators

Market Signals
Indicator
CAC
DRUG
Relative Strength Index (RSI) 66.39 43.97
Support Level $49.36 $72.08
Resistance Level $51.57 $81.00
Average True Range (ATR) 1.71 4.85
MACD 0.37 -1.57
Stochastic Oscillator 87.69 26.02

Price Performance

Historical Comparison
CAC
DRUG

About CAC Camden National Corporation

Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: